This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lynch, H. T. Articles by Lynch, J. F. Search for Related Content PubMed PubMed Citation Articles by Lynch, H. T. Articles by Lynch, J. F.

Hereditary Factors in Gynecologic Cancer

^a Department of Preventive Medicine; ^b Department of Obstetrics and Gynecology, Creighton University School of Medicine, Omaha, Nebraska, USA

Correspondence: Henry T. Lynch, M.D., Department of Preventive Medicine, Creighton University School of Medicine, 2500 California Plaza, Omaha, Nebraska 68178, USA. Telephone: 402-280-2942; Fax: 402-280-1734; e-mail: htlynch{at}creighton.edu

Cancer predisposition in some families is known to be the result of germ-line mutations. The most noteworthy hereditary gynecologic cancer syndromes include hereditary breast-ovarian cancer (HBOC) syndrome, wherein BRCA1 and BRCA2 germ-line mutations have been identified, and hereditary nonpolyposis colorectal cancer (HNPCC) of the Lynch syndrome II variant, wherein hMSH2, hMLH1, hPMS2, hMSH3, and hMSH6 germ-line mutations have been identified. DNA testing for specific cancer-associated germ-line mutations is now available for HBOC and HNPCC syndrome family members who are in the direct line of inheritance. Genetic counseling is mandatory prior to DNA testing and at the time of disclosure of findings. A patient found to be negative for the family's particular cancer-associated germ-line mutation can revert to general population screening recommendations. When a deleterious mutation is identified, the physician is able to predict a patient's lifetime susceptibility to breast and ovarian carcinomas in the HBOC syndrome or the cancers which characterize the Lynch syndrome II variant of HNPCC, particularly carcinomas of the colon, endometrium, and ovary. Management strategies can be offered which are designed to take advantage of the natural history of that distinct hereditary cancer syndrome.

We discuss the unfolding developments concerning familial and heritable susceptibilities, molecular genetics, and possible carcinogenic co-factors of the three most common gynecologic cancers: carcinomas of the uterine cervix, endometrium, and ovary. We offer rationales for management based on current epidemiologic and clinical data and emerging technologies.

Key Words. Genetics • Germ-line mutations • Genetic counseling • Gynecologic cancer • Hereditary cancer

This article has been cited by other articles:

				K.-H. Tung, M. T. Goodman, A. H. Wu, K. McDuffie, L. R. Wilkens, A. M. Y. Nomura, and L. N. Kolonel Aggregation of Ovarian Cancer with Breast, Ovarian, Colorectal, and Prostate Cancer in First-degree Relatives Am. J. Epidemiol., April 15, 2004; 159(8): 750 - 758. [Abstract] [Full Text] [PDF]

				N Kazerouni, C Schairer, H B Friedman, J V Lacey Jr, and M H Greene Family history of breast cancer as a determinant of the risk of developing endometrial cancer: a nationwide cohort study J. Med. Genet., November 1, 2002; 39(11): 826 - 832. [Full Text] [PDF]